#China #Hangzhou #Innovent Biologics #ADC facility #Altruist Biologics

Altruist Biologics Achieves Milestone with Hangzhou Facility Approval

In a significant stride towards advancing biopharmaceutical manufacturing, Altruist Biologics, a subsidiary of Innovent Biologics, has received provincial regulatory approval for its facility in Hangzhou, China. This facility is set to specialize in the segmented production of antibody-drug conjugates (ADCs). Notably, it marks the first instance of a site receiving approval from three provincial regulatory bodies, showcasing the facility's robust compliance and quality assurance protocols.

The Importance of Quality and Compliance

Dr. Kaisong Zhou, the Chairman and CEO of Altruist Biologics, emphasized the company’s commitment to quality as the cornerstone of its operations. He remarked, "Our integrated global quality system enables us to consistently deliver the highest standards of compliance, reliability, and operational excellence while supporting the evolving needs of our partners worldwide." This dedication to quality not only enhances the credibility of Altruist Biologics but also ensures that it can play a pivotal role in the development and supply of innovative therapies that can significantly impact patient health globally.

Advanced Manufacturing Capabilities

The Hangzhou site stands out with its advanced fully integrated ADC AXC bioconjugation facility. This facility is equipped to produce a variety of bioconjugates, including high-potency ADCs, catering to clinical and commercial demands with both small- and large-scale manufacturing capabilities. With its cutting-edge laboratories focused on ADC process development as well as quality control, Altruist Biologics assures seamless transitions from developmental phases to full-scale manufacturing.

Among its standout features, the facility utilizes single-use reactor systems that support conjugation scales of up to 500 liters, with plans for expansions that can accommodate up to 5,000 liters. Such versatility not only increases production efficiency but also enhances the company’s responsiveness to client needs in the biopharmaceutical landscape.

State-of-the-Art Safety Features

Safety and compliance are paramount at Altruist Biologics, and the Hangzhou facility has been designed with rigorous safety measures. It is outfitted with an automated, isolator-based aseptic filling system, along with high-containment systems that adhere to strict Occupational Exposure Limit (OEL) guidelines of 5 ng/m³. This focus on robust safety measures ensures that high-potency active pharmaceutical ingredients (APIs) can be handled safely while complying with industry regulations.

Over the years, Altruist Biologics has successfully managed more than 40 ADC and AXC projects, showcasing its extensive expertise within the ADC domain. Their portfolio includes molecules that have advanced from pre-investigational new drug (IND) status to phase three clinical trials, alongside significant production quality (PPQ) batches.

Looking Ahead

As Altruist Biologics pushes forward, it is clear that this approval reflects not just a milestone in regulatory achievement but also a commitment to innovation in biopharmaceutical manufacturing. With over a decade of experience, the company has established a robust track record, including over 100 global regulatory filings with various health authorities such as the FDA, EMA, and PMDA, among others.

The pathway ahead looks promising for Altruist Biologics, as it strives to support the growth of affordable and high-quality biopharmaceuticals for patients worldwide. With their focus on expanding capabilities and delivering excellence, they continue to reinforce their role as a leader in the biopharmaceutical manufacturing sector.

For more insights into Altruist Biologics and its capabilities, be sure to visit www.altruistbio.com.